

Medsafe consultation submission

Addition of wa	rning statements o	n labels of topic	cal
miconazole-con	taining medicines		
Name and designation			
Company/organisation name and address	The Christic	hua bo	cot
Contact phone number and email address			
I would like the comments I has specific sections of response if	eve provided to be kept confidential: f applicable)	(Please give reasons and ide	entify Yes No
(Reasons for requesting confid	dentiality must meet Official Informa	tion Act 1982 criteria)	
I would like my name to be rea	noved from all documents prior to p	publication on the Medsafe we	ebsite. Yes - No
I would like for my name not to website.	o be included within the list of submi	issions published on the Med	Isafe Yes No
	ysis of stakeholder comme	ents if you provide the	information requested
below.			
I am, or I represent, an	organisation that is based	in:	
New Zealand	☐ Australia ☐ Othe	er (please specify):	
I am, or I represent, a: (tid	ck all that apply)		
☐ Importer	☐ Manufacturer	Supplier	☐ Sponsor
Government	Researcher	☐ Professional body	☐ Industry organisation
☐ Consumer organisation	☐ Member of the public	☐ Institution (e.g. univ	rersity, hospital)
☐ Regulatory affairs consult	ant		
Health professional – plea	se indicate type of practice:	ened fractit	Tono
Other - please specify:			
Please return this form	to:	And the second s	
Or Post: Product Medsa PO Bo	tions@moh.govt.nz including t Regulation fe x 5013 gton 6145	g 'Miconazole warning s	statements' in the subject lin

Medsafe is seeking comments on:

Whether a warning statement about the interaction between warfarin and miconazole is required for all topical miconazole containing medicines available without prescription.

- If a warning is not required for all products please provide your reasoning

I think there should be a wormy on all products because the interdior is severe.

I had a patient who took microrazde for one week white an isolated.

I have a reweek white an isolated were from 2.5 -> 13

Which of the proposed warning statements about the interaction between warfarin and miconazole is preferred?

- Please provide your reasoning, this will help Medsafe when considering future warning statements

That the interaction is severe and
there people on wombon should
by use miconarde of if they
do the wombon must be monitored
Closely and dose adjust.

Please include additional pages if necessary.

Whether the statements required in Australia for intravaginal miconazole products should be included in the Label Statements Database.

- Please provide your reasoning
- Are the statements acceptable or should they be reworded?

Yes as there ance again will be an interded that could distrib the INR with Serious consequences

What is a suitable target date for implementation:

- Please provide justification

Os Soon as possible.
es Serous interate trab Could
cause people to bleed intenally